Leadership Team

Mr. Lettmann has served as our Chief Executive Officer since September 2023 and has been an investor/member of our board of directors since the company’s founding in 2015. He brings more than 20 years of experience as both a biotechnology operator and investor.

Prior to joining the Company, Mr. Lettmann was a Co-Founder and General Partner at Lightstone Ventures from 2012 to 2023, where he led investments in innovative life sciences companies. He also served as Chief Executive Officer of Promedior through its acquisition by Roche in 2020.

Mr. Lettmann has served on the boards of multiple public and private companies across the biotechnology and medical technology sectors, including ALX Oncology (NASDAQ: ALXO), Promedior (acquired by Roche), Ra Pharmaceuticals (acquired by UCB), Relievant (acquired by Boston Scientific), Tarsus (acquired by Integra Lifesciences), and Vapotherm (NASDAQ: VAPO).

He previously held investment roles as a General Partner at Morgenthaler Ventures as well as at Split Rock Partners and began his career in consulting at Accenture. Mr. Lettmann holds an M.B.A. with distinction from the University of Michigan Ross School of Business and a B.A. with honors from the University of Iowa.

Dr. Barbara Klencke has served as our Chief Medical Officer since February 2026, following her prior role as Interim Chief Medical Officer at ALX Oncology. She also previously served as a member of our board of directors. She currently serves as an independent board director of Xencor, and TScan Therapeutics. Dr. Klencke has over 30 years of experience in patient care, academic and scientific research, and clinical drug development in hematology and oncology. She has served in various executive leadership roles at a range of small, mid-sized, and large biotech companies including Sierra Oncology, Inc. (acquired by GlaxoSmithKline for $1.9B), Onyx Pharmaceuticals (acquired by Amgen for $10.4B) and Genentech, a member of the Roche Group. Prior to entering the biotechnology industry, Dr. Klencke served as an Assistant Clinical Professor of Medicine, Division of Hematology and Oncology, at the University of California, San Francisco, where she previously completed her training in hematology, oncology and internal medicine. She holds a Bachelor of Science degree from Indiana University and an M.D. from the University of California, Davis.

Mr. Knight has served as Chief Development & Operating Officer since April 2026. He brings more than 30 years of leadership experience in the biopharmaceutical industry, spanning drug development, enterprise operations, and organizational scale-up. Throughout his career, Mr. Knight has led companies through critical phases of growth, including clinical development, operational expansion, and commercialization. His experience includes roles at early-stage biotechnology companies, emerging growth organizations, and large global biopharmaceutical companies. Most recently, Mr. Knight served as Chief Development and Operating Officer at Crinetics Pharmaceuticals. Prior to that, he held senior leadership positions at Poseida Therapeutics, Halozyme Therapeutics, Amgen, Onyx Pharmaceuticals, Genentech, and Hoechst Marion Roussel (now part of Sanofi), among others. Mr. Knight holds a Master of Public Health in Biostatistics and Epidemiology and a Bachelor of Arts in Psychology from the University of Oklahoma, as well as a Bachelor of Science in Nursing from the University of Kansas.

Harish Shantharam has served as Chief Financial Officer since January 2025. He joined ALX Oncology from CymaBay Therapeutics, Inc., where he helped guide the company in its transition towards late-stage development and commercial readiness and through its $4.3 billion acquisition by Gilead Sciences, Inc. Earlier in his career, he served in roles of increasing responsibility and scope at Gilead Sciences, including as Vice President and Head of Global Commercial Finance, where he led the financial operations supporting a global $20 to $30 billion-dollar revenue business. Prior to joining Gilead, Mr. Shantharam served in various roles of increasing responsibility driving forecasting, commercial analytics and business development at Amgen. Mr. Shantharam holds an MBA in finance from UCLA Anderson School of Management and a graduate degree in Industrial Engineering from the University of Texas at Arlington. He is also a CFA charter holder.

Ms. Wong has served as our Senior Vice President Finance and Chief Accounting Officer since August 2023. Prior to 2023, she served as our Vice President Finance and Chief Accounting Officer since May 2021. Before joining ALX Oncology, Ms. Wong was with Tizona Therapeutics, Inc. from July 2016 to April 2021, where she most recently served as Vice President of Finance and Operations. Prior to Tizona, Ms. Wong was the Corporate Controller at InSite Vision Inc. from December 2008 to July 2016, the Assistant Controller at Bare Escentuals, Inc. from May 2007 to November 2008, and Director of Corporate Accounting and Financial Reporting at Dreyer’s Grand Ice Cream Holdings, Inc. from March 2002 to May 2007. Ms. Wong started her career in the audit practice at Deloitte and Touche LLP after graduating with a Bachelor of Science degree in business administration with a major in accounting from Montana State University. She is a Certified Public Accountant.